This clinical trial focuses on patients who have experienced an ischemic stroke, a condition where blood flow to the brain is blocked, often requiring urgent medical procedures. The study investigates the use of erythromycin lactobionate, a medication administered through an intravenous infusion, to help manage the stomach contents of these patients. Specifically, the trial aims to see if this medication can reduce the size of the stomach area, as measured by an ultrasound, before patients undergo a procedure called mechanical thrombectomy, which is used to remove the blood clot causing the stroke.

The purpose of the study is to evaluate how effective erythromycin lactobionate is in decreasing the stomach’s antral surface area, which is the part of the stomach closest to the small intestine. This is important because having a full stomach can complicate medical procedures. Patients who are found to have significant stomach contents, as determined by an ultrasound scan, will be included in the study. The trial will monitor changes in the stomach area before and after the thrombectomy procedure to assess the medication’s impact.

Throughout the study, various observations will be made, such as the frequency of patients with reduced stomach size and any changes in medical management strategies due to the ultrasound findings. The trial will also track any complications that may arise during the thrombectomy procedure, such as low blood pressure or breathing difficulties, and any side effects related to the administration of erythromycin lactobionate. The study is designed to provide valuable insights into the potential benefits of using this medication in stroke patients undergoing emergency procedures.